SCHEDULE: Synlogic, NEA Disclose Merger Agreement Details

New Enterprise Associates 14, L.P. and affiliated entities have filed an amendment to their Schedule 13D, detailing their support for Synlogic, Inc.'s merger with Caldera Therapeutics, Inc.

Summary

• This filing is an amendment to a Schedule 13D, originally filed on October 14, 2015, and updated through several previous amendments.
• The amendment concerns the Common Stock of Synlogic, Inc. (the 'Issuer').
• New Enterprise Associates 14, L.P. ('NEA 14') and related entities (collectively, 'Reporting Persons') hold 2,922,772 shares of Synlogic's Common Stock, representing 25.0% of the outstanding shares.
• The filing details a merger agreement entered into on July 28, 2026, between Synlogic, Caldera Therapeutics, Inc., and related entities.
• Under the agreement, Synlogic will merge with a subsidiary of Parent, and Caldera will merge with another subsidiary of Parent.
• Synlogic shareholders will receive shares of Parent Common Stock, with the exchange ratio determined by the merger agreement.
• NEA 14 and other stockholders have entered into support agreements to vote in favor of the mergers.
• NEA 14's exercise price for certain warrants was reduced to $0.70 per share, and the right to redeem warrants for cash was removed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on a merger agreement and related support and warrant amendments without new financial performance data or significant strategic shifts beyond the announced transaction.

Positives

• NEA 14 and affiliated entities are supporting a merger that is expected to result in Synlogic shareholders receiving Parent Common Stock.
• The exercise price of NEA 14's purchase warrants has been reduced to $0.70 per share.
• NEA 14 and other stockholders have committed to voting in favor of the proposed mergers.

Negatives

• NEA 14's right to require redemption of its purchase warrants for cash has been removed.
• The filing indicates that Scott D. Sandell, Forest Baskett, and Patrick J. Kerins have ceased to beneficially own 5% or more of Synlogic's Common Stock as of April 1, 2026.

Risks

• The merger is subject to the satisfaction of customary closing conditions.
• The filing does not detail specific risks associated with the merger itself, but the removal of the warrant redemption right could be viewed as a negative for NEA 14 in certain scenarios.

Future Outlook

The filing details a merger agreement where Synlogic will merge with a subsidiary of Parent, and Caldera Therapeutics will merge with another subsidiary of Parent. Synlogic shareholders will receive shares of Parent Common Stock. The specific exchange ratio is to be calculated according to the merger agreement.

Industry Context

StockSavvy.ai notes that this filing reflects a significant strategic transaction for Synlogic, involving a merger that will likely reshape its corporate structure and potentially its market position. The involvement of a major venture capital firm like New Enterprise Associates underscores the ongoing consolidation and strategic realignments within the biotechnology sector.

Stakeholder Impact

• Shareholders of Synlogic will receive shares of Parent Common Stock, subject to the terms of the merger agreement.
• NEA 14 has had its warrant exercise price reduced and its cash redemption right removed, impacting its potential future returns from warrants.

Next Steps

• Completion of the Synlogic Merger and the Caldera Merger, subject to satisfaction of closing conditions.
• Conversion of Synlogic Common Stock into Parent Common Stock.

Key Dates

Recommendation

The filing primarily concerns a merger agreement and related actions, rather than current operational performance. While the merger itself is a significant event, the details provided do not offer enough new information to warrant a buy or sell recommendation at this stage. A hold recommendation allows for further monitoring of the merger's progress and the terms of the new entity.

Keywords

Merger Agreement, Schedule 13D, Synlogic, Caldera Therapeutics, New Enterprise Associates, Support Agreements, Warrants, Capital Markets